Raymond James & Associates Tyme Technologies, Inc. Transaction History

Raymond James & Associates

  • $150 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Nov 07, 2019
SELL
$0.97 - $1.77 $10,584 - $19,314
-10,912 Closed
0 $0
Q2 2019

Aug 06, 2019
BUY
$0.96 - $1.89 $10,475 - $20,623
10,912 New
10,912 $13,000

About TYME TECHNOLOGIES, INC.

TYME Quotes by TradingView
  • Ticker TYME
  • Exchange NASDAQ
  • Shares Outstandng 172,207,008
  • Description
  • Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...
More about TYME
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email